PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis

Phase 3

Completed

Conditions: Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

Interventions: Drug: rimegepant 75 mg ODT
Drug: Matching placebo

First Posted Date: 2022-02-21

Last Posted Date: 2024-06-27

Lead Sponsor: Pfizer

Target Recruit Count: 261

Registration Number: NCT05248997

Locations: 🇺🇸
ChicagoENT, Chicago, Illinois, United States
🇺🇸
Advarra, Columbia, Maryland, United States
🇺🇸
Velocity Clinical Research, Medford, Medford, Oregon, United States

and more 35 locations

Pre-approval Single-patient Expanded Access for Elranatamab (PF-06863135)

Conditions: Multiple Myeloma

First Posted Date: 2022-02-14

Last Posted Date: 2024-08-06

Lead Sponsor: Pfizer

Registration Number: NCT05238311

PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors

Phase 1

Terminated

Conditions: Urothelial Cancer
Advanced Solid Tumors
Gastroesophageal Junction Cancer
Gastric Cancer
Non Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinomas

Interventions: Drug: PF-07265028
Biological: Sasanlimab

First Posted Date: 2022-02-10

Last Posted Date: 2024-05-31

Lead Sponsor: Pfizer

Target Recruit Count: 21

Registration Number: NCT05233436

Locations: 🇺🇸
Napa Research, Margate, Florida, United States
🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States

and more 9 locations

Voxelotor Brain Oxygenation and Neurocognitive Study

Phase 4

Withdrawn

Conditions: Sickle Cell Disease

Interventions: Drug: Voxelotor Oral Tablet

First Posted Date: 2022-02-08

Last Posted Date: 2024-08-09

Lead Sponsor: Pfizer

Registration Number: NCT05228821

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
The Children's Hospital at Montefiore, Bronx, New York, United States

Voxelotor Neurocognitive Function Study

Phase 3

Terminated

Conditions: Sickle Cell Disease

Interventions: Drug: Placebo
Drug: Voxelotor Only Product in Oral Dose Form

First Posted Date: 2022-02-08

Last Posted Date: 2024-05-02

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT05228834

Locations: 🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States

A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

Phase 2

Active, not recruiting

Conditions: BCMA
Elranatamab
Relapsed Multiple Myeloma
Refractory Multiple Myeloma
Multiple Myeloma
Bispecific
BCMA-CD3 Bispecific
Myeloma
PF-06863135
MagnetisMM-8

Interventions: Drug: Elranatamab

First Posted Date: 2022-02-08

Last Posted Date: 2024-04-16

Lead Sponsor: Pfizer

Target Recruit Count: 39

Registration Number: NCT05228470

Locations: 🇨🇳
Shenzhen Second People's Hosptial, Shenzhen, Guangdong, China
🇨🇳
Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, China
🇨🇳
Fujian Medical University Union Hospital, Fuzhou, Fujian, China

and more 17 locations

A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza

Phase 1

Completed

Conditions: Influenza, Human

Interventions: Biological: PF-07836394 Influenza saRNA
Biological: PF-07836396 Influenza saRNA
Biological: PF-07852352 Influenza saRNA 1
Biological: PF-07836395 Influenza saRNA
Biological: PF-07867246 Influenza saRNA
Biological: PF-07915048 Influenza saRNA
Biological: PF-07836391 Influenza saRNA
Biological: PF-07871987 Influenza saRNA
Biological: PF-07914705 Influenza saRNA
Biological: Placebo
Biological: Quadrivalent influenza vaccine (QIV)

First Posted Date: 2022-02-07

Last Posted Date: 2023-09-11

Lead Sponsor: Pfizer

Target Recruit Count: 442

Registration Number: NCT05227001

Locations: 🇺🇸
Great Lakes Clinical Trials - Andersonville, Chicago, Illinois, United States
🇺🇸
Pioneer Heart Institute, Lincoln, Nebraska, United States
🇺🇸
Arizona Heart Rhythm Center, Phoenix, Arizona, United States

and more 22 locations

Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies

Phase 2

Recruiting

Conditions: Head and Neck Cancer
Breast Cancer

Interventions: Drug: Palbociclib
Drug: Fulvestrant
Drug: Cetuximab
Drug: Letrozole

First Posted Date: 2022-02-07

Last Posted Date: 2024-11-12

Lead Sponsor: Pfizer

Target Recruit Count: 35

Registration Number: NCT05226871

Locations: 🇨🇳
Mackay Memorial Hospital, Taipei, Taiwan
🇲🇽
Hospital Universitario "Dr. Jose Eleuterio Gonzalez", Monterrey, Nuevo LEÓN, Mexico
🇨🇳
Hubei Cancer Hospital, Wuhan, Hubei, China

and more 13 locations

A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver Dysfunction

Phase 1

Active, not recruiting

Conditions: Moderate Hepatic Impairment
Severe Hepatic Impairment
Healthy Volunteers

Interventions: Drug: Lorlatinib

First Posted Date: 2022-02-04

Last Posted Date: 2024-08-06

Lead Sponsor: Pfizer

Target Recruit Count: 16

Registration Number: NCT05224609

Locations: 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸
Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States
🇺🇸
Genesis Clinical Research, LLC, Tampa, Florida, United States

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Colorectal Cancer

Interventions: Biological: Pembrolizumab
Drug: Encorafenib
Biological: Cetuximab

First Posted Date: 2022-02-01

Last Posted Date: 2024-11-13

Lead Sponsor: Pfizer

Target Recruit Count: 101

Registration Number: NCT05217446

Locations: 🇺🇸
Mayo Clinic Building - Phoenix, Phoenix, Arizona, United States
🇺🇸
Mayo Clinic Hospital, Phoenix, Arizona, United States
🇫🇷
Institut Régional du Cancer Montpellier, Montpellier, France

and more 106 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy